Evidence map›Paper›PMID 20031121›Full record

ArticleCellular immunology2010

A unique unresponsive CD4+ T cell phenotype post TCR antagonism.

Lindsay J Edwards, Brian D Evavold

Open access · greenAbstract read
In one paragraph

Article in Cellular immunology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Dual TCR T Cells: Identity Crisis or Multitaskers?Journal of immunology (Baltimore, Md. : 1950) · 2019
    Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Lindsay J EdwardsDepartment of Microbiology and Immunology, Emory University School of Medicine, 1510 Clifton Rd., Atlanta, GA 30322, USA.
Brian D Evavold
Emory University · US

Funding

Negative Regulatory Mechanisms for Myelin Specific T cellsR01NS062358 · NINDS · EMORY UNIVERSITY · PI EVAVOLD, BRIAN D · 2009 to 2013
$1.4M
Peptide:MHC stability and potency of T cell responsesR01AI056017 · NIAID · EMORY UNIVERSITY · PI EVAVOLD, BRIAN D. · 2005 to 2007
$1.1M
Peptide:MHC stability and potency of T cell responsesR21AI056017 · NIAID · EMORY UNIVERSITY · PI EVAVOLD, BRIAN D. · 2004 to 2004
$369k
NIAID NIH HHS R01 AI056017NIAID NIH HHS R21 AI056017NINDS NIH HHS R01 NS062358
6 · The paper itself

Abstract

The functional outcomes of the T cell's interaction with the peptide:MHC complex can be dramatically altered by the introduction of a single amino acid substitution. Previous studies have described the varied effects of these altered peptide ligands (APL) on T cell responses. These outcomes of T cell interaction with an APL include the induction of clonal unresponsiveness (anergy) and inhibition of T cell responses (antagonism). The phenotype of peptide-induced anergy, i.e. low proliferation and low IL-2 production, has been extensively described, and a number of groups have demonstrated antagonism. However, the response of T cells to an agonist ligand after encountering an antagonistic stimulus has not been previously characterized. Here, we show that T cells post-antagonism fail to proliferate but produce large quantities of IL-2 upon stimulation with their wild type ligand. This unique phenotype is not due to differences in IL-2 receptor expression or rates of apoptosis, and cannot be overcome by the addition of recombinant IL-2. The response of CD4 T cells to agonist stimulation after encountering an antagonist is a novel phenotype, and is distinct from previously described forms of anergy.

Indexed as

AnimalsCD4-Positive T-LymphocytesCell ProliferationCells, CulturedInterleukin-2MiceMice, TransgenicPeptidesPhenotypeReceptors, Antigen, T-CellReceptors, Interleukin-2Interleukin-2PeptidesReceptors, Antigen, T-CellReceptors, Interleukin-2

Identifiers

PMID20031121
PMCPMC2838172
OpenAlexW2026925599

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.